Ben Venue Laboratories prides itself on having products that are clean, clear, and cold. A subsidiary of German drug firm Boehringer Ingelheim, the company provides contract manufacturing services, including product and process development and regulatory compliance services. The company specializes in manufacturing liquid and lyophilized (freeze-dried) pharmaceuticals. Ben Venue's Bedford Laboratories division provides contract manufacturing of generic injectable pharmaceuticals. Customers include multinational drugmakers, small biotech development firms, and government agencies.

Nektar Therapeutics company was founded in 1990 and is headquartered in San Carlos, California. Nektar Therapeutics is a biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. The Company’s product pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Nektar’s research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. It creates its drug candidates by using its chemistry platform to modify the chemical structure of drugs using polymer conjugates. Nektar’s drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

AstraZeneca France does its bit to help its parent, global pharmaceutical powerhouse AstraZeneca, fight diseases from A to Z. In addition to its headquarters at Reuil Malmaison, the company operates an R&D facility for cancer treatments and packaging in Reims. The plant, which produces cancer as well as cardiovascular drugs, sends about a third of its product to Italy, the rest to North Africa and Portugal. The company's Dunkirk production plant makes Pulmicort, Symbicort, Mopral, and INexium in its chemical unit, while the pharmaceutical unit makes Bricanyl and Turbuhaler. Dunkirk ships its finished products to the US. In all AstraZeneca France, which was formed in 1975, makes and ships about 40 drugs.

De Novo Pharmaceuticals, Ltd. was incorporated in 1999 and is based in Cambridge, the United Kingdom. De Novo Pharmaceuticals, Ltd., a drug discovery company, provides computational drug design services. It focuses on small molecule therapeutics. The company provides services to drug discovery customers seeking progress from validated target to novel hits; and to medicinal chemistry groups interested in focused chemical libraries. It offers SkelGen, a chemical structure-generation platform and a suite of software tools for the analysis of structural information on a protein target and the de novo design of molecules to bind into its site, as well as for the hit and lead discovery to the pharmaceutical industry. The company offers its SkelGen for scaffold hopping, virtual high-throughput screening, focused library design, intelligent fragment linking, and low affinity fragment-based design applications. It also provides drug discovery partnerships, such as structure-based drug design, ligand-based drug design, and fragment-based drug design services, as well as focused libraries for medicinal chemistry seeking the design of focused libraries against classes of targets. In addition, the company involves in applying its SkelGen silico drug design platform to design compounds for various targets within the diabetes field.

Haw Par Corporation Limited is engaged in licensing the Tiger trademarks, and owning investments for long-term holding purposes. It has four segments: manufacturing, marketing and trading of Healthcare products; provision of leisure-related services; property rental, and investments in securities. Its healthcare division principally manufactures and distributes analgesic products under the Tiger Balm and Kwan Loong brand. Leisure division provides family and tourist oriented leisure alternatives mainly in the form of oceanariums. Property division owns and leases out several investment properties in the Asia region. Investment division engages in investing activities, mainly in quoted and unquoted securities in Asia region. In December 2009, the Company announced that it completed the dissolution of the subsidiaries Haw Par Realty Private Limited, HPH Property Sdn Bhd, Kwan Loong Industries Sdn Bhd, Haw Par Tiger Balm (Hong Kong) Limited and Kwan Loong Oils (HK) Limited.

Ambrilia Biopharma likes to work with drug candidates when they're still in the early stages of development. Once they hit late stage, the company prefers to license them out for further development. The company is also working to manufacture better formulations of existing drugs to bring in cash. Ambrilia's pipeline includes anti-virals and a handful of oncology drug candidates including generic candidates Octreotide and Goserelin. While it is shifting its focus onto anti-viral drugs, the company is continuing with clinical trials of the two oncology drugs. Mid-shift, however, the company's funds dried up and it filed for bankruptcy protection in the Canadian courts.

Biolex uses its LEX System and "Plantibodies" technologies for harvesting proteins from Lemna, an aquatic plant, and genetically transforming them into monoclonal antibodies for use in treating human diseases such as hepatitis C. Its lead drug candidate, Locteron, when combined with ribavarin, greatly reduces the viral load of the disease while causing fewer side effects. Its BLX-155 is used to dissolve blood clots; BLX-301 is designated for treating non-Hodgkin's B-cell lymphoma. Chairman Chris Hegal owns just under 25% of the company. Biolex has withdrawn its IPO filing.

Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France. Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The company's Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The company's products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated.

InterMune, Inc. company was founded in 1998 and is headquartered in Brisbane, California. InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies in pulmonology and hepatology. It offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease in the United States. The company has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes CAPACITY, a Phase III program evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF; and a research program focusing on pirfenidone analog ITMN-520. The hepatology portfolio comprises the HCV protease inhibitor compound ITMN-191, which is in Phase Ib, a second-generation HCV protease inhibitor research program; and a research program evaluating a new target in hepatology. It has license and collaboration agreements with Maxygen Holdings Ltd.; Array BioPharma, Inc.; Boehringer Ingelheim International GmbH; Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd.; Novartis Corporation; Connetics Corporation; Eli Lilly & Company; Genentech, Inc.; ALZA Corporation; Amgen Inc; and Marnac, Inc. and its co-licensor, /KDL GmbH.

Greer Laboratories, Inc. company develops and manufactures a variety of allergy immunotherapy testing and treatment materials. Greer operates through four business units: Human; Veterinary; Source Materials; and Contract Development. Greer Laboratories company's products include allergenic extracts, vials, single and multiple skin testing devices, and safety syringes, as well as source materials used for allergy testing such as dust mites, venoms, dander, molds, insects, and pollen. Greer Laboratories company began operations in 1904.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.